Journal of clinical tuberculosis and other mycobacterial diseases · 2025
The synergy of therapeutic vaccination and timely diagnosis for TB control in high-burden settings: Nunavut as a case study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdollahi Elaheh, Moghadas Seyed M, Galvani Alison P
Аннотация
BACKGROUND: Although the overall prevalence of Tuberculosis (TB) in Canada is relatively low, Indigenous communities are disproportionately burdened, with active TB rates exceeding those of Canadian-born non-Indigenous populations by more than 55-fold. In response, the Government of Canada and Inuit Tapiriit Kanatami have launched an initiative to eliminate TB among Inuit by 2030. We evaluated strategies underpinning this initiative, including the potential use of therapeutic TB vaccines that are currently undergoing clinical trials.
METHODS: We developed an agent-based model of TB transmission dynamics that includes the demographic distributions and household structure of the Nunavut population, as well as TB progression at the individual level. We simulated the model with combinations of interventions, including treatment of active cases, testing, and contact-tracing. We further evaluated the impact of vaccinating active TB cases and those identified with latent TB infection (LTBI) to project the reduction of TB incidence over a 20-year time horizon starting from 2025. In scenario analyses, we considered different vaccine efficacies, diagnostic delays, and rates of contact-tracing.
RESULTS: In the absence of a therapeutic vaccine, we estimated a maximum reduction of 20.0% (95% Uncertainty Range [UR]: 15.5% - 24.8%) in active TB incidence with a 4-week diagnostic delay and 75% contact-tracing rate, over the simulated time horizon. Vaccination of active TB cases and those identified with LTBI was projected to decrease the incidence by 87.0% (95% UR: 68.8% - 97.5%) by 2045. Contact-tracing of non-household members exhibited a marginal effect on reducing TB incidence in the presence of vaccination, especially when diagnostic delay was shortened.
CONCLUSIONS: Our findings highlight the importance of rapid TB diagnosis. The availability of therapeutic vaccines can substantially enhance TB control efforts towards achieving the elimination goal.
METHODS: We developed an agent-based model of TB transmission dynamics that includes the demographic distributions and household structure of the Nunavut population, as well as TB progression at the individual level. We simulated the model with combinations of interventions, including treatment of active cases, testing, and contact-tracing. We further evaluated the impact of vaccinating active TB cases and those identified with latent TB infection (LTBI) to project the reduction of TB incidence over a 20-year time horizon starting from 2025. In scenario analyses, we considered different vaccine efficacies, diagnostic delays, and rates of contact-tracing.
RESULTS: In the absence of a therapeutic vaccine, we estimated a maximum reduction of 20.0% (95% Uncertainty Range [UR]: 15.5% - 24.8%) in active TB incidence with a 4-week diagnostic delay and 75% contact-tracing rate, over the simulated time horizon. Vaccination of active TB cases and those identified with LTBI was projected to decrease the incidence by 87.0% (95% UR: 68.8% - 97.5%) by 2045. Contact-tracing of non-household members exhibited a marginal effect on reducing TB incidence in the presence of vaccination, especially when diagnostic delay was shortened.
CONCLUSIONS: Our findings highlight the importance of rapid TB diagnosis. The availability of therapeutic vaccines can substantially enhance TB control efforts towards achieving the elimination goal.